(Q31083696)

28 June 2017

1 reference

title

Amisulpride for schizophrenia (English)

1 reference

28 June 2017

0 references

N E Mota

1

1 reference

28 June 2017

M S Lima

series ordinal

2

1 reference

28 June 2017

B G Soares

series ordinal

3

1 reference

28 June 2017

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

28 June 2017

published in

1 reference

28 June 2017

issue

2

1 reference

28 June 2017

page(s)

CD001357

1 reference

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Safety of amisulpride (Solian): a review of 11 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Amisulpride - An Open Clinical Study of a New Benzamide in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

A standardized psychiatric assessment scale for rating chronic psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001357

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

21 January 2018

1 reference

12 December 2020

Treatment of positive and negative symptoms: pharmacologic approaches

1 reference

12 December 2020

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

12 December 2020

[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses]

1 reference

12 December 2020

Medico-economic assessment of neuroleptics in schizophrenia. Amisulpride versus haloperidol

1 reference

12 December 2020

Efficacy of low doses of atypical neuroleptics (benzamides) in defect states

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Amisulpride, neuroleptic and antinegative action

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

[Solian: evaluation of 10 years' experimentation and clinical practice]

1 reference

12 December 2020

[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature]

1 reference

12 December 2020

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis

1 reference

12 December 2020

Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

[Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia]

1 reference

12 December 2020

Use of atypical neuroleptics in child and adolescent psychiatry.

1 reference

12 December 2020

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Clinical update on amisulpride in deficit schizophrenia.

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

1 reference

12 December 2020

10.1002/14651858.CD001357

Identifiers

DOI

1 reference

28 June 2017

0 references

1 reference